Relugolix (BioDeep_00000858629)
代谢物信息卡片
化学式: C29H27F2N7O5S (623.1762356)
中文名称: 瑞卢戈利
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC
InChI: InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)
描述信息
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D000726 - Androgen Antagonists
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2092 - Gonadotropin Releasing Hormone Antagonist
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D10888
- PubChem: 10348973
- DrugBank: DB11853
- ChEMBL: CHEMBL1800159
- CAS: 737789-87-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Neal D Shore, Bryan A Mehlhaff, Michael S Cookson, Daniel R Saltzstein, Ronald Tutrone, Bruce Brown, Sophia Lu, Mark Fallick, Sarah Hanson, Fred Saad. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Advances in therapy.
2023 11; 40(11):4919-4927. doi:
10.1007/s12325-023-02634-7. [PMID: 37713020] - Daniel J George, David P Dearnaley. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
Future oncology (London, England).
2021 Nov; 17(33):4431-4446. doi:
10.2217/fon-2021-0575. [PMID: 34409852] - Yi-Fu Liu, Sheng-Qiang Fu, Yu-Chang Yan, Bin-Bin Gong, Wen-Jie Xie, Xiao-Rong Yang, Ting Sun, Ming Ma. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
Drug design, development and therapy.
2021; 15(?):639-649. doi:
10.2147/dddt.s291369. [PMID: 33623372] - Olaf Panknin, Andrea Wagenfeld, Wilhelm Bone, Eckhard Bender, Katrin Nowak-Reppel, Amaury E Fernández-Montalván, Reinhard Nubbemeyer, Stefan Bäurle, Sven Ring, Norbert Schmees, Olaf Prien, Martina Schäfer, Christian Friedrich, Thomas M Zollner, Andreas Steinmeyer, Thomas Mueller, Gernot Langer. Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.
Journal of medicinal chemistry.
2020 10; 63(20):11854-11881. doi:
10.1021/acs.jmedchem.0c01076. [PMID: 32960053] - David B MacLean, Hongliang Shi, Hélène M Faessel, Fred Saad. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
The Journal of clinical endocrinology and metabolism.
2015 Dec; 100(12):4579-87. doi:
10.1210/jc.2015-2770. [PMID: 26502357] - Kazuhiro Miwa, Takenori Hitaka, Takashi Imada, Satoshi Sasaki, Mie Yoshimatsu, Masami Kusaka, Akira Tanaka, Daisuke Nakata, Shuichi Furuya, Satoshi Endo, Kazumasa Hamamura, Tomoyuki Kitazaki. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
Journal of medicinal chemistry.
2011 Jul; 54(14):4998-5012. doi:
10.1021/jm200216q. [PMID: 21657270]